|
목적 : To evaluate the effect of topical diquafosol tetrasodium 3% ophthalmic solution (Diquas®, Santen Pharmaceutical Co., Ltd., Osaka, Japan) in patients with short tear film break up time (BUT)-type dry eye.
방법 : The subjects included 80 eyes of 40 patients with short BUT-type dry eye syndrome. The diagnosis of short BUT-dry eye was made based on clinical findings of tear film BUT values ≤ 6 sec, ocular staining score ≤ 3, and Schirmer test ≥ 5mm. The patients with Sjogren’s syndrome or ocular graft-versus-host disease (GVHD) were excluded. All subjects were treated with 3% diquafosol ophthalmic solution QID for four weeks. Dry eye symptom score, tear film BUT, and ocular staining score were measured and compared before and after treatment.
결과 : After 4 weeks of treatment, tear film BUT was increased from 3.0±1.3 sec to 4.3±1.7 sec (p<0.0001). Also, ocular staining score was reduced from 1.3±0.8 pre-treatment to 0.47±0.6 post-treatment (p<0.0001). The patients’ subjective dry eye symptom improved by diquafosol tetrasodium 3% administration (2.9±0.6 pre-treatment and 1.7±1.1 post-treatment; p<0.0001). The age of patients who showed improvement in dry eye symptom after diquafosol tetrasodium 3% was lower than that of patients who showed no change in symptom (60.6±9.21 vs. 67.5±16.1; p=0.036).
결론 : Diquafosol tetrasodium 3% solution may be effective in patients with short BUT-type dry eye by proving tear film stability and ocular surface epithelial integrity.
|